Evidence map›Paper›PMID 37007120›Full record

ArticleFrontiers in oncology2023

Effect of multimodal chemotherapy on survival of gastric cancer with liver metastasis - a population based analysis.

Xinghui Li, Zhiqiang Chen, Yue Zhang, Hong Zhang, Haiyan Niu, Cheng Zheng, Xiaoying Jing, Hui Qiao, Guanhua Wang, Wenjun Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Xinghui LiCancer Institute of the General Hospital, School of Public Health and Management, Ningxia Medical University, Yinchuan, Ningxia, China.
Zhiqiang ChenDepartment of Radiology, The First Affiliated Hospital, Hainan Medical University, Haikou, China.
Yue ZhangCancer Institute of the General Hospital, School of Public Health and Management, Ningxia Medical University, Yinchuan, Ningxia, China.
Hong ZhangCancer Institute of the General Hospital, School of Public Health and Management, Ningxia Medical University, Yinchuan, Ningxia, China.
Haiyan NiuDepartment of Pathology, The First Affiliated Hospital, Hainan Medical University, Haikou, China.
Cheng ZhengCancer Institute of the General Hospital, School of Public Health and Management, Ningxia Medical University, Yinchuan, Ningxia, China.
Xiaoying JingCancer Institute of the General Hospital, School of Public Health and Management, Ningxia Medical University, Yinchuan, Ningxia, China.
Hui QiaoCancer Institute of the General Hospital, School of Public Health and Management, Ningxia Medical University, Yinchuan, Ningxia, China.
Guanhua WangCancer Institute of the General Hospital, School of Public Health and Management, Ningxia Medical University, Yinchuan, Ningxia, China.
Wenjun YangCancer Institute of the General Hospital, School of Public Health and Management, Ningxia Medical University, Yinchuan, Ningxia, China.
Ningxia Medical University General Hospital · CNHainan Medical University · CNNingxia Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Limited efforts have been made to evaluate the effect of multimodal chemotherapy on the survival of gastric cancer patients with liver metastases (LMGC). This study aimed to identify prognostic factors in LMGC patients and the superiority of multimodal chemotherapy with respect to overall survival (OS) in these patients. Methods: We conducted a retrospective cohort study of 1298 patients with M1 stage disease between January 2012 and December 2020. The effects of clinicopathological variables and preoperative chemotherapy (PECT), postoperative chemotherapy (POCT), and palliative chemotherapy on survival in patients with liver metastases (LM group) and non-liver metastases (non-LM group) were compared. Results: Of the 1298 patients analysed, 546 (42.06%) were in the LM group and 752 (57.94%) were in the non-LM group. The median (interquartile range) age was 60 (51-66) years. The 1-year, 3-year and 5-year overall survival (OS) rates in the LM group were 29.3%, 13.9%, and 9.2%, respectively, and those in the non-LM group were. 38.2%, 17.4%, and 10.0%, respectively (P < 0.05, > 0.05, and > 0.05, respectively.) The Cox proportional hazards model revealed that palliative chemotherapy was a significant independent prognostic factor in both the LM and non-LM groups. Age ≥55 years, N stage, and Lauren classification were also independent predictors of OS in the LM group (P < 0.05). Palliative chemotherapy and POCT were associated with improved OS compared with PECT in the LM group (26.3% vs. 36.4% vs. 25.0%, P < 0.001). Conclusion: LMGC patients had a worse prognosis than non- LMGC. Number of metastatic sites more than 1, liver and other metastatic sites, no CT treatment and HER2-negative had a poor prognosis. LMGC patient may benefit more from palliative chemotherapy and POCT than from PECT. Further well-designed, prospective studies are needed to validate these findings.

Indexed as

gastric cancerliver metastasesoverall survivalpalliative chemotherapypostoperative chemotherapypreoperative chemotherapyprognosis

Identifiers

PMID37007120
PMCPMC10061116
OpenAlexW4327602283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.